Jerry Avorn, MD

Jerry Avorn, MD

Professor of Medicine, Harvard Medical School

Co-Director, PORTAL

Jerry Avorn is Professor of Medicine at Harvard Medical School, Co-Director of PORTAL, and Chief Emeritus of the Division of Pharmacoepidemiology and Pharmacoeconomics, which he founded. A general internist, geriatrician, and drug epidemiologist, he pioneered the use of health care claims data to study patterns of medication use and outcomes, and developed the concept of academic detailing (educational outreach to prescribers) to improve medication use. His research examines the factors that shape physicians’ drug choices, the identification and prevention of adverse drug effects, and the interaction between evidence, regulation, and economics in medication use.

Dr. Avorn is the author or co-author of over 600 papers in the medical literature on medication use and its outcomes, and is one of the most highly-cited researchers working in the area of medicine and the social sciences. His book Rethinking Medications: Truth, Power, and the Drugs You Take was published by Simon & Schuster in 2025, preceded by Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs, published by Knopf in 2004. He has served as president of the International Society for Pharmacoepidemiology and on the Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines.

Dr. Avorn completed his undergraduate training at Columbia University, received his MD from Harvard Medical School, and completed a residency in internal medicine at Beth Israel Hospital in Boston.

Featured Work

Talk bubble graphics representing commentary and opinion.

The 25th Anniversary of a Nearly Unknown Health Policy Turning Point

Avorn J - New England Journal of Medicine

  • Price, Value, and Access
A grassroots campaign by clinicians in the late 1990s nearly succeeded in mandating universal health care coverage in Massachusetts, laying the foundation for later reforms like “Romneycare” and the Affordable Care Act. Citizen-driven efforts can spark major policy changes, even with limited resources, offering lessons for today’s ongoing challenges in expanding access to affordable health care.
View Source
Talk bubble graphics representing commentary and opinion.

Op-Ed: Corporate Support Cannot Make Up for Threats to the NIH Budget

Avorn J - STAT

  • Innovation Incentives and Competition
Phamaceutical industry funding cannot substitute for robust public investment in biomedical research, especially from the NIH. Industry support is often limited to product-driven, patentable research and can restrict open scientific communication, whereas publicly funded research enables broad dissemination of basic scientific research.
View Source
Talk bubble graphics representing commentary and opinion.

Op-Ed: The Trouble with ‘Do Your Own Research’ for Drugs

Avorn J - MedPage Today

  • Price, Value, and Access
  • Regulation and Clinical Evidence
The author critiques the notion that individual patients or physicians can independently evaluate drug efficacy, highlighting the complexity of clinical trial data and a lack of public access to the full evidence manufacturers submit for regulatory review. Bypassing FDA oversight risks exposing patients to ineffective or harmful treatments, while raising questions about who would be expected to pay for such therapies.
View Source